Biobubble, Inc.

Biobubble, Inc., headquartered in Fort Collins, Colorado, manufactures modular biocontainment and cleanroom enclosures for federal health, research, and agricultural agencies as a prime contractor competing predominantly in full-and-open procurements without set-aside designation. A self-certified small disadvantaged business and Subchapter S corporation, Biobubble operates as a sole proprietor in federal markets, with no subcontract footprint; all 75 awards in the source data are prime contracts.

Biobubble's capability portfolio centers on benchtop biocontainment enclosures, freestanding negative-pressure containment units, aerosol containment enclosures with HEPA filtration, and architecturally integrated cleanroom systems engineered to meet biosafety level 2 and higher containment standards. Representative work includes a $29,800 sole-source firm-fixed-price purchase order from the National Institute of Allergy and Infectious Diseases for a benchtop biocontainment enclosure supporting HIV research at the Vaccine Research Center (awarded January 2, 2025), a $52,745 total-small-business-set-aside purchase order from USDA Agricultural Research Service for a freestanding negative-pressure containment enclosure at the National Poultry Research Center in Watkinsville, Georgia (awarded April 28, 2023), a $37,787 purchase order from the Department of Veterans Affairs for an aerosol containment enclosure (awarded March 13, 2024), and two recent National Cancer Institute purchase orders for benchtop biocontainment enclosures valued at $18,650 and $20,000 (awarded March 19, 2026 and July 21, 2026, respectively).

Customer concentration is heavily skewed toward civilian health and research agencies. The Food and Drug Administration leads across both count and dollars, accounting for 13 awards worth $546 thousand combined potential value (45% of award volume among the top five customers). The Department of the Army Medical Command follows with 10 awards totaling $271 thousand; the Centers for Disease Control and Prevention, National Cancer Institute, and Department of Veterans Affairs round out the active set. Across the full portfolio, Biobubble serves 23 distinct customer agencies, reflecting the broad distribution of federal biocontainment equipment procurement across research and health-support organizations. The primary NAICS category is All Other Miscellaneous Manufacturing (41 awards), with Laboratory Equipment and Supplies dominating the PSC categorization (59 awards).

Activity has remained sparse and episodic in recent years — one award in 2025 and two in 2026 — after a longer establishment period dating to 1991. Only one award (the July 2026 National Cancer Institute purchase order, $20,000) reaches ultimate completion within the next twenty-four months, presenting minimal recompete cliff exposure in the near term. Combined potential value across all 75 awards stands at $2.8 million, with combined obligated dollars at $2.9 million, indicating consistent delivery execution across purchase orders rather than large contingent-ceiling contracts. Biobubble does not appear on government-wide vehicles, agency IDIQs, or BPA schedules; all work flows through direct purchase orders awarded on a transactional basis.